# A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ

> **NCT00189254** · — · COMPLETED · sponsor: **MEDA Pharma GmbH & Co. KG** · enrollment: 72 (—)

## Conditions studied

- Actinic Keratoses

## Interventions

- **DRUG:** Imiquimod

## Key facts

- **NCT ID:** NCT00189254
- **Lead sponsor:** MEDA Pharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 72 (—)
- **Last updated:** 2022-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189254, "A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00189254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*